Literature DB >> 24649211

Time course of serum C-reactive protein levels during induction chemoradiotherapy and its correlation with treatment response and survival in patients with advanced esophageal squamous cell carcinoma.

Hitoshi Fujiwara1, Atsushi Shiozaki1, Akinobu Furutani1, Masayuki Yoneda1, Takeshi Kubota1, Shuhei Komatsu1, Daisuke Ichikawa1, Kazuma Okamoto1, Yasutoshi Murayama1, Yoshiaki Kuriu1, Hisashi Ikoma1, Masayoshi Nakanishi1, Toshiya Ochiai1, Eigo Otsuji1.   

Abstract

Preoperative serum C-reactive protein (CRP) levels have been shown to be of prognostic significance in patients with advanced esophageal carcinoma. However, the clinical significance of serum CRP levels in patients with unresectable or marginally resectable tumors in the absence of induction therapy has not been fully elucidated in relation to treatment response and prognosis. Thirty-four patients with clinical T3-T4 esophageal squamous cell carcinoma who underwent induction chemoradiotherapy (CRT) followed by esophagectomy were enrolled in this retrospective study. Serum CRP levels were measured during the course of CRT, i.e., prior to, during (1, 2, 3 and 4 weeks following initiation) and after CRT (prior to surgery). The association between CRP levels, CRT response and survival was analyzed. Elevated serum CRP levels exhibited a favorable decrease 2-3 weeks following CRT initiation in pathological responders and CRP ≤0.3 mg/dl at 2 and 3 weeks following CRT initiation, as well as prior to surgery, was significantly correlated with responders. In patients with pretreatment CRP >0.3 mg/dl (67.6% of patients in this study), CRP ≤0.3 mg/dl at 2 and 3 weeks following CRT initiation predicted responders with accuracies of 87.0 and 73.9%, respectively. In the univariate survival analysis, CRP levels 3 weeks following CRT initiation, as well as CRP levels prior to surgery and pathological stage, were significant prognostic factors, although CRP levels prior to surgery was the only independent prognostic factor in the multivariate analysis. Serum CRP levels during the course of CRT may be of prognostic and predictive significance for the CRT response in patients with unresectable or marginally resectable esophageal squamous cell carcinoma who undergo induction CRT.

Entities:  

Keywords:  C-reactive protein; chemoradiotherapy response; esophageal carcinoma; serum

Year:  2013        PMID: 24649211      PMCID: PMC3915279          DOI: 10.3892/mco.2013.84

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  15 in total

1.  Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer.

Authors:  Hitoshi Fujiwara; Kentaro Suchi; Shinichi Okamura; Hiroko Okamura; Seiji Umehara; Momoko Todo; Atsushi Shiozaki; Takeshi Kubota; Daisuke Ichikawa; Kazuma Okamoto; Toshiya Ochiai; Yukihito Kokuba; Teruhisa Sonoyama; Eigo Otsuji
Journal:  J Surg Oncol       Date:  2011-01-01       Impact factor: 3.454

2.  Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion.

Authors:  Giovanni de Manzoni; Corrado Pedrazzani; Felice Pasini; Marco Bernini; Anna Maria Minicozzi; Simone Giacopuzzi; Antonio Grandinetti; Claudio Cordiano
Journal:  J Surg Oncol       Date:  2007-03-01       Impact factor: 3.454

Review 3.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

4.  Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma.

Authors:  T Nozoe; H Saeki; K Sugimachi
Journal:  Am J Surg       Date:  2001-08       Impact factor: 2.565

5.  Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.

Authors:  Julie G Izzo; Usha Malhotra; Tsung-Teh Wu; Joe Ensor; Rajyalakshmi Luthra; Jeffrey H Lee; Stephen G Swisher; Zhongxing Liao; K S Clifford Chao; Walter N Hittelman; Bharat B Aggarwal; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-01-09       Impact factor: 44.544

6.  Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

Authors:  Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

7.  Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus.

Authors:  M Yano; T Tsujinaka; H Shiozaki; M Inoue; Y Doki; M Yamamoto; E Tanaka; T Inoue; M Monden
Journal:  J Surg Oncol       Date:  1999-01       Impact factor: 3.454

8.  Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma.

Authors:  Takashi Kobayashi; Masanori Teruya; Tomokazu Kishiki; Daisuke Endo; Yoshiharu Takenaka; Hozumi Tanaka; Kenji Miki; Kaoru Kobayashi; Koji Morita
Journal:  Surgery       Date:  2008-09-26       Impact factor: 3.982

9.  Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma.

Authors:  Masanori Ikeda; Shoji Natsugoe; Shinichi Ueno; Masamichi Baba; Takashi Aikou
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

10.  Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation.

Authors:  J G Izzo; X Wu; T-T Wu; P Huang; J-S Lee; Z Liao; J H Lee; M S Bhutani; W Hofstetter; D Maru; M-C Hung; J A Ajani
Journal:  Dis Esophagus       Date:  2008-11-19       Impact factor: 3.429

View more
  1 in total

Review 1.  Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review.

Authors:  Chang-Juan Tao; Gang Lin; Ya-Ping Xu; Wei-Min Mao
Journal:  J Cancer       Date:  2015-09-15       Impact factor: 4.207

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.